PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 08/26/2019

Pipeline Type

New Drugs in Development

Phase Of Development

Phase 2

Sponsors and Collaborators

Icahn School of Medicine at Mount Sinai

Mechanism of Action

Mechanism Description

inhibitor of the Ras-ERK pathway.

Populations Tested In

Phelan-McDermid Syndrome (PMS)

Other Resources

Special FDA Designation

Nonprofit or Government Support

N/A

Nonprofit or Government Support Description

N/A

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A

Location of Clinical Trials

New York City, Icahn School of Medicine at Mount Sinai

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.